Table 2.
Initial Visit Assessment of Symptoms, Treatment, and COVID-19 Testing
| n | % | |
| All Persons (N=69) | ||
| Had exposure risk only (no symptoms) | 3 | 4 |
| Had symptoms | 66 | 96 |
| Received treatment | 35 | 51 |
| Sent for COVID-19 PCR testing | 29 | 42 |
| Type of Symptom (N=69) | ||
| Cough | 55 | 80 |
| Fever | 22 | 32 |
| Shortness of breath | 24 | 35 |
| Sore throat | 20 | 29 |
| Myalgias | 7 | 10 |
| Chills | 4 | 6 |
| Loss of smell or taste | 3 | 4 |
| Nausea, vomiting, or diarrhea | 7 | 10 |
| Headache | 0 | 0 |
| Runny nose or congestion | 20 | 29 |
| Other (eg, wheezing) | 7 | 10 |
| Type of Treatment (N=69) | ||
| Cough medication | 19 | 28 |
| Asthma inhaler | 17 | 25 |
| Decongestants | 13 | 19 |
| Antibiotics | 8 | 12 |
| Oseltamivir (Tamiflu®) | 1 | 1 |
| COVID-19 Testing (N=29) | ||
| Nasopharyngeal PCR (0 of 29 positive) | 29 | 42 |
| IgM antibody (1 of 1 positive)a | 1 | 1 |
Abbreviations: COVID-19, Coronavirus disease 2019; PCR, polymerase chain reaction
a
One person had an initial negative PCR test but a subsequent positive IgM antibody test.